ESC Congress 2018: MITRA-FR Finds No Benefit Of MitraClip In Severe Secondary MR
Patients with severe secondary mitral regurgitation treated with MitraClip and medical therapy have the same rate of death or unplanned hospitalization for heart failure at one year as patients treated with medical therapy alone, results of MITRA-FR show. Abbott, as well as other companies developing transcatheter mitral-repair technology, will now look to the COAPT trial to establish MitraClip's benefits on clinical outcomes.
You may also be interested in...
ESC Congress 2018 Wrap-Up: Medtronic's Arctic Front; B. Braun's SeQuent Please; Biotronik's Orsiro Stent
Almost 33,000 cardiology professionals attended the 2018 European Society of Cardiology Congress last week in Munich. The meeting included 4,500 abstracts, including 17 late-breaking clinical trials, six clinical trial updates, and 20 registries. Here are some of the highlights of interest to the medtech industry.
PRELUDE feasibility study of LivaNova's Caisson transseptal transcatheter mitral valve replacement (TMVR) system is complete and the company the INTERLUDE CE Mark trial has begun, the company announced. The company is now working with the US FDA to finalize the protocol for the ENSEMBLE US pivotal trial.
Early data from Abbott's CE mark study of its mitral valve replacement technology Tendyne shows the device's potential in reducing mitral regurgitation in severe mitral regurgitation patients.